COR

Cencora, Inc.
$330.95
-6.27 (-1.86%)
Mkt Cap 64.39B
Volume 1,017,372
52W Range 244.82-377.54
Sector Healthcare
Beta 0.57
EPS (TTM) 13.52 USD
P/E Ratio 24.48
Revenue (TTM) 332.77B USD
Rev Growth (5Y) +11.1%
EPS Growth (5Y) +2.0%
AlphaVal · Fair Value
What we estimate one share is worth
$137.87
Overvalued strong signal
140.0% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B+
Stable Earnings Power
77.6 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 321.33B 293.96B 262.17B 238.59B 213.99B 189.89B 179.59B 167.94B 153.14B 146.85B 135.96B 119.57B
Net Income 1.55B 1.51B 1.75B 1.70B 1.54B (3.40B) 855.37M 1.66B 414.48M 1.43B (134.89M) 276.48M
EPS 8.02 7.60 8.62 8.15 7.48 -16.60 4.07 7.61 1.67 6.73 -0.62 1.22
Free Cash Flow 3.21B 3.00B 3.45B 2.21B 2.23B 1.84B 2.03B 1.07B 1.02B 2.71B 3.69B 1.20B
FCF / Share 16.55 15.10 16.88 10.59 10.82 8.97 9.68 4.93 4.68 12.79 16.94 5.27
Operating CF 3.88B 3.48B 3.91B 2.70B 2.67B 2.21B 2.34B 1.41B 1.49B 3.18B 3.92B 1.46B
Total Assets 76.59B 67.10B 62.56B 56.56B 57.34B 44.27B 39.17B 37.67B 35.32B 33.59B 27.74B 21.53B
Total Debt 10.75B 6.65B 6.82B 7.59B 8.75B 4.98B 4.49B 4.66B 3.79B 4.46B 3.74B 2.00B
Cash & Equiv 4.39B 3.23B 2.69B 3.53B 2.55B 4.60B 3.37B 2.49B 2.44B 2.74B 2.17B 1.81B
Book Value 1.51B 645.94M 522.00M (211.56M) 223.35M (1.02B) 2.88B 2.93B 2.06B 2.13B 616.39M 1.96B
Return on Equity 1.03 2.34 3.34 N/A 6.89 N/A 0.30 0.57 0.20 0.67 -0.22 0.14
COR News
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Sep 04, 2026 12:46 PM · zacks.com
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?
Sep 04, 2026 08:36 AM · zacks.com
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
Sep 04, 2026 06:56 AM · zacks.com
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Sep 03, 2026 12:56 PM · zacks.com
Cencora's Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs
Sep 02, 2026 04:30 AM · businesswire.com
Connor Clark & Lunn Investment Management Ltd. Invests $841,000 in Cencora, Inc. $COR
Aug 31, 2026 01:13 AM · defenseworld.net
Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance
Aug 23, 2026 10:22 AM · seekingalpha.com
Advisors Capital Management LLC Takes $748,000 Position in Cencora, Inc. $COR
Aug 21, 2026 11:10 PM · defenseworld.net
"Trumpflation" Is Real -- and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.
Aug 19, 2026 03:50 AM · fool.com
Why Cencora (COR) is a Top Value Stock for the Long-Term
Aug 12, 2026 06:41 AM · zacks.com